The spinoff originating from the Institute of Solid State Physics (ISSP UL) has successfully secured €3.3 million in non-dilutive funding, partially from state support under the Important Projects of Common European Interest (IPCEI) initiative in the healthcare sector, known as “Tech4Cure”.
Cellbox Labs has rapidly become a pioneer in developing micro-engineered “mini-organs” grown on microfluidics chips to replicate human physiology without animal testing. The newly secured funding will support four strategic developments:
Scaling automated gut-on-chip models in pharma-grade throughput with Altis Biosystems.
Embedding oxygen and pH sensors directly into chips to deliver real-time data.
Benchmarking biosimilar testing on pancreatic islet models under dynamic conditions.
Building digital twin simulations alongside ESQlabs and MPSlabs to enhance predictive power of in vitro data.
Cellbox Labs represents a shift in drug testing – moving away from animal models toward scalable, human-relevant, and AI-compatible solutions. We at ISSP UL are immensely proud of the team’s progress and are excited to see further innovations emerge from their journey.
